Real‐world use of continuous glucose monitoring in people with type 2 diabetes and chronic kidney disease or on dialysis
Authors' conclusion
CGM use was associated with the identification of hypoglycaemia and improvements in HbA1c in people with T2D and CKD. These real-world data demonstrate the importance of CGM technology to high-risk individuals with diabetes and CKD.
Study context
- Population
- Adults with T2D on MDI (≥2 insulin injections/day) and chronic kidney disease (CKD) stage 3–5 (eGFR <60, on renal replacement therapy or post-renal transplant) on continuous glucose monitoring (CGM), tertiary diabetes renal clinic, January 2023–September 2024; median age 64.0 (IQR 56.0–71.0) years
- Participants
- 177 adults
- Exposure
- Post-CGM vs pre-CGM initiation
- Outcome
- Time below range (<3.9 mmol/L)
Methodological detailssingle-centre, pre-post comparison
- Single-centre
- Pre-post comparison
Main finding
As reported in the abstract
P = 0.007
Observational data: associations, not effects.
Further findings
HbA1c
P < 0.001
HbA1c (%) Pre-CGM 8.0, 7.0-9.4% · Post-CGM 7.8, 6.9-8.8%
HbA1c reduction
- Participants with HbA1c reduction
- 114/177 (64.4%)
Safety
Hypoglycaemia leading to insulin dose reduction revealed by CGM
- Participants with hypoglycaemia leading to insulin dose reduction
- 91/177 (51.4%)
Original publication
Real‐world use of continuous glucose monitoring in people with type 2 diabetes and chronic kidney disease or on dialysis. Diabet Med. Published 18 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →